3SBio's (HKG:1530) unit Shenyang Sunshine Pharmaceutical will obtain the commercialization rights for HER2 ADC drug DB-1303 from Duality Biologics (Shanghai) for various indications in China, Hong Kong, and Macau, a Monday Hong Kong bourse filing said.
Duality Biologics is a clinical-stage innovative biopharmaceutical company mainly engaged in the research and development of antibody-drug conjugates therapeutic agents for the treatment of patients with cancer or autoimmune diseases.
HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that can be found on the surface of some cancer cells.
DB-1303 is designed to treat cancers that have high levels of HER2 expression, such as certain types of breast, gastric, and endometrial cancers. The drug combines an anti-HER2 monoclonal antibody with a topoisomerase I inhibitor, which helps to disrupt the cancer cells' DNA and inhibit their growth.
Shenyang Sunshine will make upfront fees and research, development, and sales milestone payments as part of the cooperation agreement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。